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Abstract
Background: Age-related macular degeneration (AMD), a chronic neurodegenerative and neovascular retinal disease, is the
leading cause of blindness in elderly people of western European origin. While structural and functional alterations in
mitochondria (mt) and their metabolites have been implicated in the pathogenesis of chronic neurodegenerative and
vascular diseases, the relationship of inherited variants in the mitochondrial genome and mt haplogroup subtypes with
advanced AMD has not been reported in large prospective cohorts.
Methodology/Prinicipal Findings: We examined the relationship of inherited mtDNA variants with advanced AMD in 1168
people using a three-stage design on samples from 12-year and 10-year prospective studies on the natural history of age-
related eye disease. In Stage I we resequenced the entire genome in 99 elderly AMD-free controls and 215 people with
advanced AMD from the 12-year study. A consistent association with AMD in 14 of 17 SNPs characterizing the mtDNA T
haplogroup emerged. Further analysis revealed these associations were driven entirely by the T2 haplogroup, and
characterized by two variants in Complex I genes (A11812G of MT-ND4 and A14233G of MT-ND6). We genotyped T
haplogroups in an independent sample of 490 cases and 61 controls from the same study (Stage II) and in 56 cases and 246
controls from the 10-year study (Stage III). People in the T2 haplogroup were approximately 2.5 times more likely to have
advanced AMD than their peers (odds ratio [OR]=2.54, 95%CI 1.36–4.80, P#0.004) after considering the totality of evidence.
Findings persisted after considering the impact of AMD-associated variants A69S and Y402H (OR=5.19, 95%CI 1.19–22.69,
P#0.029).
Conclusion: Loci defining the mtDNA T2 haplogroup and Complex I are reasonable targets for novel functional analyses and
therapeutic research in AMD.
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Age-related macular degeneration (AMD) is the leading cause of
blindness in elderly people of western European ancestry [1,2].
Evidence implicating the role of mitochondria (mt) in AMD
pathogenesis has emerged over the past 2 decades [3] and the
molecular genetics of this concept are now being investigated. A
coding variant for respiratory Complex I defining the mitochon-
drial T haplogroup (4917G) was associated with an increased
likelihood of having AMD in a U.S.-based study of 280 people
with AMD and 280 age-matched controls [4]. While analyses from
an Australian population-based cohort did not suggest association
of any major European haplotype with advanced AMD, low
accrual of endpoints, may have constrained inference [5–7].
Crosstalk between mitochondrial and nuclear genomes is a
germane issue as independent teams report that the product of
the AMD-associated LOC387715/ARMS2 of the nuclear genome
localizes to mitochondria [8,9]. While structural and functional
alterations in mitochondria and their metabolites have been
implicated in the pathogenesis of chronic neurodegenerative and
vascular diseases [10,11], the relationship of inherited variants in
the mitochondrial genome and mt haplogroup subtypes with
advanced AMD has not been reported in large prospective
cohorts. We applied a rapid high-throughput method for this
purpose on the basis of six lines of evidence: 1) cells most affected
in AMD (retinal pigment epithelium (RPE) and photoreceptors)
are densely packed with mitochondria; 2) ultrastructure of RPE
and photoreceptor mitochondria is altered in people with AMD
[12]; 3) mitochondrial metabolism yields the primary source of
reactive oxygen and nitrogen species (RONS) in RPE and
photorector cells [13]; 4) RONS target RPE and photoreceptor
mitochondrial and nuclear DNA, chromatin, and lipids [13] and
are capable of inducing somatic mutations that accumulate over
time [11,13]; 5) the retinal apoptosome is dominated by the
mitochondrial pathway [13,14]; and 6) our 3640-person multi-
center clinical trial demonstrated efficacy of a number of
antioxidant vitamins in reducing the likelihood of progression to
sight-threatening advanced AMD [15]. We now report a 2.5-fold
increased likelihood of having advanced AMD among people
carrying variants in mt DNA T2 haplogroup-associated loci. The
respective T2 variants are 11812G and 14233G of NADH
ubiquinone oxidoreductase genes MT-ND4 (mitochondrially
encoded NADH dehydrogenase subunit 4) and MT-ND6 (subunit
6).
Results
In Stage I, we applied a resequencing microarray to examine
the complete sequence of the mitochondrial genome in a sample of
215 cases and 99 controls from The Age-Related Eye Disease
Study (AREDS). The term ‘AREDS A’ is used to designate this
cohort. We identified 998 unique variants and analyzed all 315
SNPs that were both called reliably at $90% of samples and
present in at least 1% of cases or controls. Seventeen SNPs yielded
associations with advanced AMD at P#0.05 (Table 1). We were
intrigued to observe that all 12 variants with P-values#0.005
partially defined the mtDNA haplogroup T (Figure 1); nine of
these SNPs uniquely characterized this haplogroup. A T
haplotype-AMD relationship has been reported previously [4].
The T haplotype can be subdivided into T1 and T2 groups, with
T1 defined by presence of the 4917G and 11812A variants and T2
defined by presence of 4917G and 11812G.
Table 2 contains haplogroup frequencies and odds ratios (ORs)
from analyses of T haplogroup-AMD relationships. Demographic
characteristics of the original and replicate samples are given in
Table S1. We applied multivariable logistic regression models to
examine the likelihood that T1 and T2-associated loci occurred
more frequently in people with advanced AMD than in AMD-free
controls after simultaneously considering the impact of age-, sex-,
and smoking history. People in the AREDS A cohort carrying the
T1-defining variants (4917G/11812A) were not more likely than
their peers to have advanced AMD (OR=1.43, 95%CI 0.26–
7.81, 2-sided P#0.68). However, there was a 10.5-fold increased
likelihood having advanced AMD if they carried the T2 variants
(4917G/11812G, OR=10.46, 95%CI 2.35–46.63, 2-sided
P#0.002).
In Stage II we validated our findings by genotyping A4917G
and A11812G in an independent AREDS sample of 490 cases and
61 controls. The term ‘AREDS B’ is used to designate this cohort.
We used exact methods to confirm that allele frequencies for
A4917G and A11812G were not significantly different across
AREDS A and AREDS B. T1-associated SNPs were balanced
across cases and controls in both samples. T2 distributions show
that the advanced AMD group contained a higher proportion of
people with 11812G and 4917G in each sample: 4917G/11812G
existed in 2.02% of 99 controls vs. 14.42% of 215 cases in AREDS
A and in 1.64% of 61 controls vs. 7.96% of 490 cases in AREDS
B. Change in magnitude and precision of ORs was negligible after
concurrent adjustment for age, sex, and smoking history. As in the
AREDS A cohort, people in the T1 haplogroup were equally likely
to have advanced AMD as their peers. The OR for advanced
AMD in the sex-, age-, and smoking-adjusted model for T1 in
AREDS B was 0.64 (95%CI 0.17–2.52, 1-sided P#0.27). Results
for the T2 association were also concordant: OR for advanced
AMD in the sex-, age-, and smoking-adjusted model for T2 in
AREDS B was 6.12 (95%CI 0.73–51.22, 1-sided P#0.05). To
obtain a more accurate assessment of AMD risk associated with
the T2 haplogroup, we pooled samples from both AREDS A and
AREDS B. As ORs were not different (P=0.98 for T1 and 0.18
for T2, see Methods for details) and the study design was identical
for AREDS A and AREDS B, we estimated associations in the
entire sample. Results remained unchanged and precision was
enhanced; for T2 OR=5.26 (95%CI 1.62–17.09, 2-sided
P#0.006).
In Stage III we genotyped A4917G and A11812G in Blue
Mountains Eye Study (BMES) participants with advanced AMD
(n=56) or who were $74 years-of-age and AMD-free (n=246).
T1 frequency was 1.23% (95%CI 0.45%–3.6%) in the AMD-free
group and 3.57% (95%CI 1.10%–12.11%) in the advanced AMD
group. Sex-, age-, and smoking-adjusted multivariable models
yielded a non-significant increased odds of having advanced AMD
among people carrying the T1-defining variants (OR=4.40,
95%CI 0.69–27.96, 1-sided P#0.058). T2 frequency was 7.72%
(95%CI 5.0%–11.6%) for the AMD-free group and 10.71%
(95%CI 5.1%–21.5%) for the advanced AMD group. T2-
advanced AMD measures of association did not attain statistical
significance within the BMES cohort (OR=1.35, 95%CI 0.50–
3.64, 1-sided P#0.277). Combining our independent replication
samples (AREDS B and BMES) yielded an OR=1.87 (95%CI
0.83–4.02, 1-sided P#0.064).
T2 haplogroup frequency for AREDS (8.21%, 95%CI 6.57%–
10.23%) and BMES (8.28%, 95%CI 5.68%–11.94%) was similar
and within limits reported from U.S. cohorts of European ancestry
[16]. Table 2 indicates T2 frequency among people with AMD
was also similar between studies. Applying the meta-analytic
method of DerSimonian & Laird [17] yielded a combined OR of
3.40 (95%CI 1.02–11.28, 2-sided P#0.046). We also combined
raw data from AREDS A, AREDS B, and BMES in our final
multivariable logistic regression models with a term for sample
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AREDS and BMES cohorts were not statistically different
(P=0.08). T2-AMD results persisted and were of the same
magnitude of those from the DerSimonian & Laird estimates
(OR=2.54, 95%CI 1.36–4.80, 2-sided P#0.004). Considering the
totality of evidence from these 2 large longitudinal studies, people
carrying the T2 variant (G allele for 11812) were more likely than
their AMD-free peers to have advanced AMD.
We tested the independence of the T2-advanced AMD
relationship by simultaneously entering A11812G with AMD
susceptibility loci Y402H and A69S in age-, sex-, and smoking-
adjusted logistic regression models. The distribution of A11812G
Figure 1. Distribution of age- and sex-adjusted P-values for all 315 mitochondrial DNA variants with minor allele frequencies .1%
from the AREDS A cohort. P-values were obtained from logistic regression analyses modeling the likelihood of having increased frequency of the
less commonly observed allele in people with advanced AMD. The magnitude of 2log10 P-values was highest for SNPs partially or completely
characterizing the T haplotype (see red symbols). Fourteen of the 17 variants in this category yielded the strongest associations in the entire sample.
Among these T-haplotype-associated variants those represented by a square symbol lead to changes in protein structure. Details of these variants
exist in Table 1. SNPs selected for analysis in our replication samples are indicated with arrows.
doi:10.1371/journal.pone.0005508.g001
Mitochondrial Genome and AMD
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5508did not vary by Y402H or A69S (Table S2). AREDS data on
both Y402H and A69S existed for 601 people with advanced
AMD and 132 AMD-free people. Modeling these variants had a
negligible effect on our findings for T2 (OR=5.19 (95%CI 1.84–
22.69, 2-sided P#0.028)). Data on Y402H existed for 52 BMES
participants with advanced AMD and 238 of their AMD-free
peers. The T2-advanced AMD relationship persisted after adding
these data to the pooled AREDS A and AREDS B cohort
(OR=2.66 (95%CI 1.29–5.49, 2-sided P#0.008). We conclude
that presence of the Y402H or A69S risk allele did not alter the T2
haplogroup-advanced AMD association.
Discussion
Our aim was to elucidate novel mtDNA-AMD relationships and
we consider our findings most valuable for exploratory purposes. BMES was a
population-based cohort and although T2 frequency was similar to
AREDS in the overall sample and AMD groups, this study
contributed only ,10% of our advanced AMD cases. While
members of AREDS and BMES cohorts were all of European
origin we did not have specific information on ethnic background.
This may partially explain our findings, as clear differences in
allele frequencies exist between European populations by
geographic origin of ancestry [18]. Risk estimation will be most
relevant with forthcoming analyses on additional samples from
population-based cohorts. Both T2-associated variants identified
in our comprehensive scan are in genes encoding core subunits
embedded in the hydrophobic domain of complex I (NADH
ubiquinone oxidoreductase) within the oxidative phosphorylation
(OXPHOS) system. Phylogenetic data and primary sequence
comparisons indicate genes for these two subunits are evolution-
arily conserved in mammals [19]. The A11812G variant exists at
locus 351 of codon 3 of MT-ND4. MT-ND4 codes for NADH
dehydrogenase subunit 4 – a homologue of the E. coli NDH-1
proton translocation module polypeptide nuoM. NuoM shares
strong sequence similarity with the antiporter multiple resistance
and pH locus (Mrp) D of numerous Bacillus strains and for this
reason is thought to have been recruited as a functional unit
(instead of evolving from gene duplications). The nuoM link with
this class of antiporter suggests a H
+ channel composition and
activity within proton translocation systems. MT-ND4 has also
been implicated in ubiquinone biosynthesis and is essential for
complex I assembly [20]. A rare MT-ND4 variant characterizing
the T2 haplogroup existed in a small case study of people with
Leber hereditary optic neuropathy (LHON), a blinding disease
[21]. The A14233G variant exists at locus 147 of codon 3 of MT-
ND6 (NADH dehydrogenase subunit 6). MT-ND6 products
compose elements of the proton translocation module. Like MT-
ND4, MT-ND6 is essential for complex I assembly [20]. MT-ND6
is thought to be incorporated into complex I early in initial phases
of the assembly process, while MT-ND4 follows after assembly of a
number of intermediate subunits [19].
Neither A11812G nor A14233G are non-synonymous substitu-
tions. While there is currently no evidence to conclusively
demonstrate that these variants may impact translation dynamics
for complex I (and thereby alter the bioenergetic system of the
Table 1. Associations between mitochondrial variants and advanced AMD.
Variant
locus Gene mt Function Minor Variant Frequency (%) OR (95%CI) P-Value Haplogroup
No AMD Adv. AMD
73 Non-Coding D-loop 48 (48) 77 (36) 0.58 (0.35–0.95) 0.030 H, HV, V
930 MT-RNR1 12S rRNA 1 (1) 19 (9) 12.52 (1.60–97.74) 0.016 –
1888 MT-RNR2 16S rRNA 3 (3) 33 (15) 7.92 (2.27–27.65) 0.001 T
4216 MT-ND1 Complex I 11 (11) 58 (27) 3.19 (1.56–6.53) 0.002 T, J
4917 MT-ND2 Complex I 4 (4) 35 (16) 6.15 (2.04–18.52) 0.001 T
8697 MT-ATP5 Complex V 5 (5) 34 (16) 4.84 (1.74–13.40) 0.003 T
10463 MT-TR tRNA-Arg 3 (3) 33 (15) 7.92 (2.27–27.65) 0.001 T
11251 MT-ND4 Complex I 11 (11) 57 (26) 3.10 (1.51–6.35) 0.002 T, J
11812 MT-ND4 Complex I 2 (2) 29 (14) 10.45 (2.35–46.82) 0.002 T2
14233 MT-ND6 Complex I 2 (2) 29 (14) 10.35 (2.32–46.10) 0.002 T2
14905 MT-CYB Complex III 3 (3) 33 (15) 7.92 (2.27–27.65) 0.001 T
15452 MT-CYB Complex III 11 (12) 57 (27) 3.12 (1.51–6.40) 0.002 T, J
15607 MT-CYB Complex III 3 (3) 34 (16) 8.09 (2.33–28.14) 0.001 T
15928 MT-TT tRNA-Thr 3 (3) 34 (16) 8.02 (2.30–27.87) 0.001 T
16093 Non-Coding D-loop 6 (6) 4 (2) 0.27 (0.07–1.00) 0.050 –
16304 Non-Coding D-loop 3 (3) 22 (10) 3.95 (1.11–14.05) 0.034 H5
16126 Non-Coding D-loop 13 (13) 58 (27) 2.51 (1.28–4.91) 0.007 T1, J
Odds ratios (ORs) are ratios of the odds of having the less commonly observed allele among people with advanced (Adv.) age-related macular degeneration (AMD) to
the odds of having this variant within their AMD-free peers. Values higher than 1.0 suggest an increased likelihood of having advanced AMD associated with presence of
the less commonly observed allele. Advanced AMD was classified as neovascular AMD or geographic atrophy of the macula (n=215); No AMD (n=99), these people
were essentially free of age-related macular abnormalities with a drusen area of less than 5 small drusen (,63 um diameter) in both eyes; Models are age-, sex-, and
smoking-adjusted. Age at the final fundus photograph used for phenotyping was modeled as a continuous variable; Complex I, NADH ubiquinone
oxidoreductase;Complex III, ubiquinol cytochrome c oxidoreductase; Complex V, F1F0ATPase/ATP synthase; rRNA, ribosomal RNA; tRNA, transfer RNA. P-values are 2-
sided and represent the minimum false positive rate when testing the hypothesis that people with AMD have different distributions of the less commonly observed
allele than their AMD-free peers. Based on these results we examined distributions of SNPs A4917G and A11812G in an independent sample (see Table 2).
doi:10.1371/journal.pone.0005508.t001
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for examining this possibility. We also note that 1–2% of the mt
genome does not yield high-quality sequence data, and our
resequencing algorithm is not designed to detect insertions/
deletions. Thus, it is possible that the T2-associated functional
variant is actually in an unsequenced region or a copy number
variant, so that evaluating this possibility is a high priority.
Somatic mtDNA mutations induced in the PolgA
mut mouse cause
premature aging phenotypes without altering reactive oxygen
species production, suggesting that respiratory chain dysfunction
itself is the etiologic factor in many age-related diseases [22]. In
addition to possible bioenergetic defects, the volume of reactive
metabolites from the OXPHOS system may be altered through
inherited variants and this may damage mitochondrial ultrastruc-
ture or induce redox sensitive genes implicated in cell survival and
pathologic angiogenesis.
AREDS data were used in the first genome-wide association
study to identify the Y402H variant of the CFH gene as a strong
risk factor for advanced AMD [23]. We had data on Y402H in
709 cases and 373 controls for whom genotypes on T2-associated
variants existed. We examined the main effects of the 402 risk
allele and T2 variants in this population and then evaluated the
possibility that our findings on T2 could be explained by existence
of a higher frequency of the 402 risk allele among people with T2
haplotype. Main effects for Y402H with a T2 term in age-, sex-,
and smoking-adjusted models (OR=2.63, 95%CI 2.06–3.36, 2-
sided P-value#0.0001) were similar to those from extant reports.
Results for T2 (OR=2.66, 95%CI 1.29–5.49, 2-sided P-
value#0.008) were similar to those we report for data combined
from AREDS A+AREDS B. In summary, modeling Y402H and
T2 simultaneously did not alter the standard error of either
variable and yielded a negligible change in the magnitude of ORs.
A strong AMD-LOC387715 (A69S) association also exists in the
AREDS cohort [24]. We had data on A69S and T2 variants for
615 cases and 136 controls and applied these for the same
purposes guiding us in the Y402H analyses. The main effect of the
A69S risk allele on advanced AMD (OR=3.32, 95%CI 2.36–
4.67, 2-sided P-value#0.0001 in the model described above was
similar to those reported in independent samples; in our analyses
T2 retained significance (OR=3.99, 95%CI 1.19–13.45, 2-sided
P-value#0.026). Modeling Y402H, A69S and T2 simultaneously
did not impact the variance in either variable and resulted in no
appreciable change to the magnitude of ORs (Y402H=2.49,
P#0.001; A69S=3.22, P#0.001; T2=5.19 (95%CI 1.19–22.69),
2-sided P#0.029). We conclude that presence of the Y402H or
A69S risk allele does not alter the effect of the T2 haplogroup on
advanced AMD (respective P-values for the Y402H*T2 and
A69S*T2 interactions are #0.45 and #0.29). Table S2 contains
cross-tabulations of T2 with Y402H and A69S.
In conclusion, we used a rapid high-throughput method to
determine that prevalence of two variants defining the mtDNA T2
haplogroup was higher in people with sight-threatening AMD
than in their healthy peers. Both variants existed in highly
conserved genes of NADH ubiquinone oxidoreductase (Complex
I). If these results are substantiated by functional studies
demonstrating OXPHOS deficits in people with AMD, they
Table 2. Measures of association for advanced AMD with variants characterizing T haplogroups.
Haplogroup Sample Origin Sample Size Haplogroup Frequency (%)
Multivariable
OR (95% CI) P-value*
No AMD/Adv. AMD No AMD Adv. AMD
T1 (4917G/11812A)
AREDS A 99/215 2 (2.02) 5 (2.33) 1.43 (0.26–7.81) 0.682
AREDS B 60/480 4 (6.67) 15 (3.13) 0.64 (0.17–2.52) 0.265*
AREDS A+B 159/695 6 (3.77) 20 (2.88) 0.97 (0.37–2.52) 0.946
BMES 243/56 3 (1.23) 2 (3.57) 4.40 (0.69–27.96) 0.058*
AREDS B+BMES 303/536 7 (2.31) 17 (3.17) 1.17 (0.33–4.26) 0.401*
AREDS+BMES Combined Data 402/751 9 (2.24) 23 (3.06) 1.31 (0.50–3.39) 0.582
AREDS+BMES Meta-analysis 402/751 9 (2.24) 23 (3.06) 0.96 (0.32–2.85) 0.943
T2 (4917G/11812G)
AREDS A 99/215 2 (2.02) 31 (14.42) 10.46 (2.35–46.63) 0.002
AREDS B 61/490 1 (1.64) 39 (7.96) 6.12 (0.73–51.22) 0.048*
AREDS A+B 160/705 3 (1.88) 68 (9.65) 5.26 (1.62–17.09) 0.006
BMES 246/56 19 (7.72) 6 (10.71) 1.35 (0.50–3.64) 0.277*
AREDS B+BMES 307/546 20 (6.51) 45 (8.24) 1.87 (0.83–4.02) 0.064*
AREDS+BMES Combined Data 406/761 22 (5.42) 74 (9.72) 2.54 (1.36–4.80) 0.004
AREDS+BMES Meta-analysis 406/761 22 (5.42) 74 (9.72) 3.40 (1.02–11.28) 0.046
Odds ratios (ORs) comparing the proportion of people with variants characterizing the T1 or T2 haplogroups and advanced (Adv.) AMD relative to their AMD-free peers.
The mtDNA T1 haplogroup is defined by the presence of the 4917G variant and the presence of the 11812A variant. The T2 haplogroup is defined by the presence of
4917G and 11812G. The multivariable models are adjusted for age, sex, and smoking history (ever vs. never). Models for the AREDS+BMES cohorts contain a term for
sample origin (study).
*P-values are 2-sided, unless marked with an asterisk; 1-sided P-values (for replication analyses) are for tests on the hypothesis that people with AMD are more likely to
carry haplogroup-defining variants. All samples are composed of participants self-identified as being of non-Hispanic white origin. Demographic characteristics of the
samples exist in Table S1. AREDS samples A and B are independent. ORs from the meta-analysis are from random effects models. Respective values for T1 and T2 from
fixed-effects models are 0.85 (95%CI 0.37–1.96, 2-sided P,0.705) and 2.72 (95%CI 1.29–5.74, 2-sided P,0.009). AREDS=Age-Related Eye Disease Study. BMES=Blue
Mountains Eye Study.
doi:10.1371/journal.pone.0005508.t002
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exhibiting antioxidant and mitotropic properties.
Materials and Methods
Our inferences are based on a 3-stage research design in 406
AMD-free people and 762 people with advanced AMD. We
applied a mitochondrial genome-sequence scan, evaluation of
single marker- and mtDNA haplogroup-AMD associations, and
validation with representative SNPs in independent cohorts
examined in large prospective studies designed to systematically
measure AMD endpoints. All data are from elderly self-identified
white, non-Hispanic U.S. and Australian residents participating in
The Age-Related Eye Disease Study (AREDS) [15] or The Blue
Mountains Eye Study (BMES) [5–7]. The primary outcome of this
report is advanced AMD, defined as presence of geographic
atrophy or neovascular AMD at any time during the 12-year
course of AREDS or geographic atrophy or neovascular AMD at
any time during the 10-year course of BMES. We ascertained
phenotype in AREDS annually from stereoscopic color fundus
images using a standardized and validated protocol. For the
BMES, advanced AMD was also determined from stereoscopic
color fundus images using a standardized and validated protocol;
data were collected at baseline and at 5- and 10-years-post
enrollment for some participants. The likelihood of having
advanced AMD increases 2-to-6 fold after age 74. To optimize
the discovery of AMD susceptibility loci we thus selected controls
from the oldest AREDS and BMES participants who were
essentially free of age-related macular abnormalities. AMD-free
controls had no or less than 5 small drusen (,63 um diameter) in
both eyes across the 12- and 10-year follow-up periods; in
addition, these people had bilateral visual acuity of 20/32 or better
and were free of any clinically significant ocular pathology. Before
study initiation, the AREDS protocol was approved by a Data and
Safety Monitoring Committee and by the Institutional Review
Board for each clinical center. Prior to enrollment, informed
consent was obtained from all participants. All clinical investiga-
tion was conducted according to the principles expressed in the
Declaration of Helsinki.
Subjects and Study Design
Details of the Age-Related Eye Disease Study (AREDS) study
design and methods exist elsewhere [15,25]. AREDS was a multi-
center study designed to assess the clinical course of, and risk
factors for, the development and progression of AMD by collecting
data on possible risk factors, measuring changes in visual acuity,
photographically documenting changes in macula status, and
assessing self-reported visual function. Eleven retinal specialty
clinics enrolled participants aged 55 to 80 years from November
1992 through January 1998, and followed them until April 2001.
A natural history study extending to December 2005 was
implemented in April 2001.
Details of the Blue Mountains Eye Study (BMES) exist
elsewhere [5–7]. BMES is a population-based survey of common
eye disease and vision within a noninstitutionalized urban
population aged 49 years or older. The catchment area includes
2 post-code areas of the Blue Mountains region west of Sydney,
Australia. The study commenced in 1991.
Outcomes
AREDS Report 1 contains information on the process of
outcome ascertainment [25]. Advanced AMD cases met the
following criteria [26]: (1) presence in either eye of geographic
atrophy or neovascular AMD defined as photocoagulation or
other treatment for choroidal neovascularization (based on clinical
center reports); or (2) photographic documentation of any of the
following; non drusenoid retinal pigment epithelial detachment,
serous or hemorrhagic retinal detachment, hemorrhage under the
retina or retinal pigment epithelium, and/or subretinal fibrosis
either at baseline or during the course of the study. BMES cases
and controls were ascertained by the methods applied in AREDS
and represent analogous phenotypes. A recent BMES report
provides details of outcome assessment for the advanced AMD
group [5–7].
Our central aim was identification of AMD susceptibility loci
and haplogroups. Our AMD-free group had good vision in both
eyes and no existing eye disease. Controls were selected to be the
oldest participants with DNA available who had no or less than 5
small drusen (,63 mm diameter) and no pigmentary abnormalities
in both eyes at all visits for which fundus photographs were
gradable. Both eyes had visual acuity of 20/32 or better measured
by a standard protocol, ocular media was clear enough for good
quality fundus photographs, and there was absence of any ocular
disorder that might obscure assessment of either AMD or lens
opacities.
Our controls have three distinguishing characteristics that make
them the best existing comparison group for this purpose:
N Phenotype was determined annually over a 12-year period
(AREDS) or across a 10-year period with a standardized
protocol by multiple professional graders who were masked to
phenotypic information from previous years. Adjudication
with a standardized protocol occurred when discrepancies
emerged.
N The criteria for AMD-free classification (,5d r u s e no f
#63 mm in both eyes for the entire follow-up period) is
stringent relative to those applied in previous association
studies for AMD.
N The age of the AREDS AMD-free group is in the range that
AMD prevalence increases ,3 times (from ,4% in those aged
74-to-79 to ,12% in those aged $80-years) in population-
based studies.
The likelihood of having AMD increases 2-to-6 fold after age 75
and it was therefore essential to select our oldest AMD-free
participants to reduce the false negative rate that would otherwise
result from non-random misclassification in the youngest members
of the control group. The mean age (6standard error) of controls
in our combined cohorts was 77.7 (60.29) years. R. Klein and M.
Knudtson at the Beaver Dam Eye Study (BDES) applied our
definition of AMD-free people in their population-based sample of
U.S. residents of European ancestry. Only 3.3% of the 4,628
participants were both aged 75-to-86 years and AMD-free [27].
7.9% of BDES participants were older than 70-years-of-age and
AMD-free, by our definition. It is important to note that outcome
ascertainment for AREDS took place at University of Wisconsin
Fundus Photograph Reading Center. Furthermore, the BMES
AMD photographic grader trained at this center.
Pooled AREDS and BMES Samples
We examined the disparity between ORs in AREDS A,
AREDS B, and BMES cohorts by calculating the difference
between their corresponding logarithms (log odds) and dividing
this value by the square root of the standard errors of the log odds.
This ratio has an approximate standard normal distribution under
the hypothesis of no difference between samples, and P-values are
computed accordingly. Results from these analyses provided an
empirical basis to pool samples.
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BMES sample was 8.21% (95%CI 6.78%–9.94%); this value is
within expected limits of those reported for U.S.-based cohorts of
European ancestry [16]. Haplotype frequency for T2 in AMD-free
participants was 5.42% (95%CI 3.61%–8.07%) reflecting the
stringent nature in selection of the sample of participants in our
control group. There are relatively few people without signs of
AMD who are both older than 75-years-of age and of European
ancestry. In The Beaver Dam Eye Study (BDES [27]), the largest
population-based study on AMD in U.S. residents of European
ancestry, 3.34% (95%CI 2.84%–3.94%) of the 4628 participants
were both 75-to-86 years of age and AMD-free by our
ascertainment criteria.
Power Analysis
We applied the method of Samuels et al. [28] to derive power
estimates for our combined AREDS sample. In the pooled
AREDS sample there was approximately 83.5% power to detect
an increase in allele frequency of the size observed assuming
presence of 11 mtDNA European haplogroups and an a-level of
0.05. We report this conservative estimate, based on assumed
variation in 11 European haplogroups. Power estimates at a=0.05
for 5 haplogroups (the number defining 90% of the AREDS
cohort) and 2 haplogroups (the number tested in Stage II and
Stage III) yielded slight increases in power to 84.5% and 86.0%,
respectively. In the pooled AREDS+BMES sample there was
approximately 97.5% power to detect an increase in allele
frequency of the size observed assuming presence of 11 mtDNA
European haplogroups and an a-level of 0.05.
Meta-Analysis
We used the method of DerSimonian and Laird [17] to
compute combined ORs. Cochran’s Q statistic for homogeneity
suggested that the magnitude of effect in ORs differed only as a
function of sampling error and permitted application of the fixed-
effect model (Q=3.98, df=2, p=0.14). Since Q is susceptible to
inaccuracy due to the small number of studies analyzed we used
the I
2 index to quantify the degree of heterogeneity attributed to
between-studies variation. For T2, 50% of the total variability in
the magnitude of OR can be explained by actual heterogeneity
between studies. On this basis we selected the point estimate
derived from the random-effects model.
Mitochondrial Resequencing
Resequencing of the entire mitochondrial genome was per-
formed using the Affymetrix GeneChip Human Mitochondrial
Resequencing Array 2.0 according to manufacturer’s protocols.
PCR and hybridization conditions are as previously described
[29]. Grid-alignment and genotype calls were assigned using RA
Tools Ver1.0.5 (http://www.dpgp.org/RA/ra.htm) based on the
ABACUS algorithm under the assumption of a haploid genome
[30].
Genotyping
In the AREDS cohort the 11812G variant always existed with
the 14233G variant. We believe that the likelihood that an
individual would carry only one of these variants is extremely low,
given the absence of this event in any of the 400 independent
mitochondrial samples we have analyzed for work outside of the
current study.
Genotyping for mtSNPs 4917 and 11812 were performed using
TaqMan Assays by Design (Applied Biosystems). Primers and
probes are listed below:
SNP Forward Primer Sequence Reverse Primer Sequence
MITO4917 GACATCCGGCCTGCTTCT TGGGTTTG-
GTTTAATCCACCTCA
MITO11812 ACAGTCGCATCATAATCCTCTCTCA
GAGGTTAGCGAGGCTTGCT
SNP Reporter 1 Sequence Reporter 2 Sequence
MITO4917 CTCCCTCACTAAACGTAAG TCCCTCA-
CTAGACGTAAG
MITO11812 ACTTCAAACTCTACTCCCAC TTCAAA-
CTCTGCTCCCAC
Supporting Information
Table S1 Demographic and life-style characteristics of AREDS
and BMES samples. All participants are self-identified as being of
being of non-Hispanic white origin. AMD=age-related macular
degenration; Adv. AMD=advanced AMD (geographic atrophy
and or neovascular) AREDS=Age-Related Eye Disease Study;
BMES=Blue Mountains Eye Study; GA=geographic atrophy;
NV=neovascular; stderr=standard error. AREDS A and
AREDS B cohorts are independent. Demographic data are for
all participants with T1 or T2 base calls.
Found at: doi:10.1371/journal.pone.0005508.s001 (0.02 MB
XLS)
Table S2 Cross-tabulations of percent allelic frequency in T2-
associated variants for Y402H and A69S
Found at: doi:10.1371/journal.pone.0005508.s002 (0.02 MB
XLS)
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